The invention relates to the technical field of
biomedicine, in particular to a
monoclonal antibody specifically combined with EsxB and a therapeutic
reagent. The
monoclonal antibody comprises a light chain variable region and a
heavy chain variable region, the light chain variable region comprises three complementary determining regions VLCDR1, VLCDR2 and VLCDR3, the
heavy chain variable region comprises three complementary determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an
amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.1, and the
heavy chain variable region is an
amino acid sequence which is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical with SEQ.ID.NO.2; the therapeutic
reagent comprises a
monoclonal antibody, a single-chain antibody, a human-mouse
chimeric antibody or a
humanized antibody; the
monoclonal antibody with high specificity, high
neutralization activity and high protection force for EsxB provided by the invention has the characteristic of mediating complement-dependent cytotoxic effect, has excellent in-vivo
antibacterial activity, and can support the construction of an anti-EsxB chimeric or humanized
genetic engineering antibody with
neutralization activity.